- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG — Recruiting • Phase III • Cardiology / Cardiovascular • NCT04045665.
- The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass….
- Sponsor: Icahn School of Medicine at Mount Sinai.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to…
- : * Patients of age ≥18 years who undergo isolated CABG for coronary artery disease * POAF that persists for >60 minutes or is recurrent (more than one episode) within 7 days after the index CABG surgery
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.